Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Clinical-trials-phase-ii crawled time : 18:00 save search
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
Published: 2024-04-22 (Crawled : 18:00) - biospace.com/
LTRN | News | $5.53 -4.16% 84K
|
Health Technology
|
| O: 6.74%
H: 5.26%
C: 0.35%
lung pharma japan approval cancer cell for trial
Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
Published: 2024-01-08 (Crawled : 18:00) - biospace.com/
SHPH | $0.373 -3.87% 10K
|
|
| O: 4.42%
H: 0.0%
C: -16.11%
fda approval treatment pharmaceuticals trial glioblastoma
New Phase 2 Data Demonstrate Potential Benefit of Nipocalimab for Pregnant Individuals at High Risk of Early-Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
Published: 2023-06-26 (Crawled : 18:00) - biospace.com/
JNJ | News | $148.66 -0.6% 5.2M
|
Health Technology
|
| O: -0.3%
H: 0.0%
C: -0.82%
disease risk potential
Sermonix Pharmaceuticals Announces Article Comparing ‘Traditional’ to ‘Just-in-Time’ Trial Enrollment Models Is Published in JCO Clinical Cancer Informatics
Published: 2023-06-26 (Crawled : 18:00) - biospace.com/
LLY | News | $733.3 -1.66% 1.4M
|
Health Technology
|
| O: 1.4%
H: 0.0%
C: -2.69%
LGND | $70.74 1.22% 63K
|
Health Technology
|
| O: -0.3%
H: 1.85%
C: -0.84%
cancer pharmaceuticals trial
Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001
Published: 2023-06-22 (Crawled : 18:00) - biospace.com/
ALZN | $0.729 0.47% 10K
|
Professional, Scientific, and T...
|
| O: -3.75%
H: 7.58%
C: 1.79%
al001 positive trial results
LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma
Published: 2023-04-24 (Crawled : 18:00) - biospace.com/
LIXT | $3.56 10.56% 14K
|
Health Technology
|
| O: -4.26%
H: 6.4%
C: -0.63%
lb-100 treatment trial doxorubicin
BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100
Published: 2023-04-24 (Crawled : 18:00) - biospace.com/
BRTX | $1.26 -5.97% 57K
|
Professional, Scientific, and T...
|
| O: 1.28%
H: 1.77%
C: 0.25%
brtx-100 study
Altamira Therapeutics Announces Publication of Positive Results from Phase 2 Trial with AM-125 in Acute Vestibular Syndrome in Leading Peer Reviewed Journal
Published: 2023-04-12 (Crawled : 18:00) - biospace.com/
CYTO | $1.46 -7.6% 2.9M
|
Manufacturing
|
| O: 35.61%
H: 45.25%
C: 17.32%
am-125 positive publication trial therapeutics results
Verrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for the Treatment of Basal Cell Carcinoma
Published: 2023-04-12 (Crawled : 18:00) - biospace.com/
VRCA | $6.75 -1.46% 69K
|
Health Technology
|
| O: 1.59%
H: 0.0%
C: -3.29%
vp-315 cell treatment pharmaceuticals study
Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
Published: 2023-04-04 (Crawled : 18:00) - biospace.com/
ALZN | $0.729 0.47% 10K
|
Professional, Scientific, and T...
|
| O: 2.04%
H: 1.0%
C: -0.5%
alzn002 vaccine alzheimer’s dementia immunotherapy trial initiated
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629 in Chronic Cough
Published: 2023-03-30 (Crawled : 18:00) - biospace.com/
ALDX | $3.895 -0.38% 360K
|
Health Technology
|
| O: 0.0%
H: 2.43%
C: 0.53%
adx-629 trial therapeutics phase 2
First Wave BioPharma Announces First Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase FormulationTopline data anticipated by mid-2023
Published: 2023-03-09 (Crawled : 18:00) - biospace.com/
FWBI | $3.12 28K
|
Manufacturing
|
| O: 13.52%
H: 5.46%
C: -6.2%
biopharma adrulipase trial
Clene's Nanocrystal ALS Treatment Bounces Back with Positive Data
Published: 2023-03-09 (Crawled : 18:00) - biospace.com/
CLNN 4 | $0.3351 210K
|
|
| O: 10.0%
H: 0.7%
C: -5.59%
treatment als back positive
Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Multiple System Atrophy
Published: 2023-03-08 (Crawled : 18:00) - biospace.com/
IKT | $1.64 3.8% 51K
|
Health Technology
|
| O: 6.47%
H: 6.65%
C: -8.09%
fda system ikt-148009 lifted therapeutics clinical hold
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette CessationTopline Data Expected in 2Q 2023
Published: 2023-03-08 (Crawled : 18:00) - biospace.com/
ACHV | $4.525 0.56% 23K
|
Health Technology
|
| O: -0.59%
H: 2.38%
C: 1.79%
sciences life expected trial
Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis
Published: 2022-12-16 (Crawled : 18:00) - biospace.com/
EQ | $1.76 2.33% 40K
|
Health Technology
|
| O: -0.33%
H: 0.76%
C: -3.44%
study phase 2 ulcerative colitis
Seagen Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma
Published: 2022-12-12 (Crawled : 18:00) - biospace.com/
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.69%
H: 6.19%
C: 5.6%
adcetris immunotherapy trial results
Omega Therapeutics Announces First Patient Dosed in Landmark MYCHELANGELO™ I Trial of OTX-2002 in Hepatocellular Carcinoma and Other Solid Tumor Types Associated with the MYC Oncogene
Published: 2022-10-27 (Crawled : 18:00) - biospace.com/
OMGA | $2.33 -0.43% 130K
|
|
| O: 2.16%
H: 5.56%
C: -7.05%
otx-2002 trial therapeutics
Lexicon Pharmaceuticals Highlights Scientific and Medical Presentations Relating to Its Successful Phase 2 Proof-Of-Concept Study of LX9211 in Painful Diabetic Neuropathy
Published: 2022-09-20 (Crawled : 18:00) - biospace.com/
LXRX | $1.585 -1.55% 1.4M
|
Health Technology
|
| O: 0.4%
H: 4.03%
C: 2.02%
lx9211 pharmaceuticals study diabetic phase 2
I-Mab Announces Oral Presentation of Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
Published: 2022-09-06 (Crawled : 18:00) - biospace.com/
IMAB | $1.805 0.28% 67K
|
Health Technology
|
| O: 0.17%
H: 0.68%
C: -5.57%
cd47 antibody presentation phase 2
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
CSSE 4 | $0.3831 151.54% 190M
|
Consumer Services
CZOO | $11.04 121.24% 11M
|
LICN | $0.9107 62.63% 14M
|
BOF | $1.87 59.83% 100M
|
AMST | $3.18 59.0% 67M
|
Technology Services
MTC | $3.31 47.77% 7.7M
|
Technology Services
MULN | News | $3.915 43.41% 12M
|
Information
WIMI | $1.04 43.37% 17M
|
Technology Services
SKIL 4 | $8.045 40.89% 230K
|
Information
RILY | $30.01 38.17% 11M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.